Document is current
Any future updates will be listed below
-
Authors
Kernder, Anna https://orcid.org/0000-0002-7742-7526
Thiele, Katja https://orcid.org/0000-0003-1655-0595
Chehab, Gamal https://orcid.org/0000-0001-7309-2370
Schneider, Matthias
Callhoff, Johanna https://orcid.org/0000-0002-3923-2728
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 28 November 2022
Accepted: 20 April 2023
First Online: 1 June 2023
Declarations
:
: GC, MS and AK have received grant support to their institution from GSK, AstraZeneca and UCB Pharma. AK has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma GmbH, Rheumatologische Fortbildungsakademie and Streamed up! GmbH; support for attending meetings and/or travel from AGJR and Pfizer. GC has received support for attending meetings from Pfizer; personal fees/honoraria from lectures, presentations and/or advisory boards from Otsuka Pharma, AstraZeneca, GSK and Rheumatologische Fortbildungsakademie. MS has received personal consulting fees and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, GSK, Janssen-Cilag, Lilly, Novartis, Otsuka, Pfizer, Protagen, Roche, Sanofi-Aventis and UCB. JC has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Rheumatologische Fortbildungsakademie and Janssen.
: The application was approved by the Ethics Committee of the Charité (number EA1/196/06).
